FDA rejects AstraZeneca’s diabetes combo and demands more data

Damian Garde The FDA wants to see more clinical trial data on AstraZeneca's new combination diabetes treatment, the company said, likely delaying a potential launch by more than ...

Cempra tanks on ‘positive’ Phase III for pneumonia antibiotic

Damian Garde Cempra's in-development treatment for bacterial pneumonia measured up to the now-generic antibiotic moxifloxacin in a Phase III study, but the combination of alarming ...

Pharma’s newest nemesis? Nestlé works at the intersection of food and drugs to attack illnesses

Eric Palmer If Big Pharma didn't already have enough to worry about, with patent cliffs, drug price investigations and reluctant payers, it now will have to face the onslaught of ...

Pfizer responds to FiercePharma

Alok Saboo Tracy Staton wrote an article on Thursday, based on a piece in Forbes. Pfizer took exception to our article and sent a statement. FiercePharma News

Strongbridge raises $25M in a downsized IPO

Damian Garde Drug developer Strongbridge Biopharma cleared $ 25 million in an IPO, bringing in less than a third of the cash it once sought as biotech companies continue to struggle ...

Boehringer wins FDA approval for its Pradaxa antidote with eyes on a bigger market share

Damian Garde Boehringer Ingelheim picked up an FDA nod for an injection designed to reverse the effects of its blockbuster anticoagulant Pradaxa, marking the first approval for an antidote ...

Boehringer looks for Pradaxa boost from now FDA-approved antidote

Carly Helfand The lack of an antidote to reverse the effects of new-age anticoagulants has kept some doctors from prescribing them. But now, Boehringer Ingelheim is hoping that'll ...

Biotech notches another $2B VC quarter, but can it last?

Damian Garde Biotech venture capital investments remain on pace for a record year after racking up another $ 2 billion in the third quarter, but some current shakiness in the public ...

Valeant CEO J. Michael Pearson delivers expansion news to Bausch + Lomb employees

Eric Palmer Valeant Pharmaceuticals CEO J. Michael Pearson took a break this week from defending the company's price hike strategies to deliver good news to employees ...

Roche backs €19M CNS round; CRUK puts £20M into cancer vax; In womb stem cell trial to start

Nick Paul Taylor In this week's EuroBiotech Report, Ysios Capital led a €19.4 million ($ 21.7 million) investment in Minoryx Therapeutics with the support of Roche Venture ...

FDA’s review of BI’s Pradaxa was ‘lax’ and ‘permissive,’ watchdog claims

Carly Helfand Boehringer Ingelheim's next-gen anticoagulant, Pradaxa, has been plagued by safety worries that have cropped up since its 2010 FDA approval. And according to one watchdog ...

J&J says it has plenty of firepower for M&A, buyback or no buyback

Carly Helfand Johnson & Johnson may be embarking on a $ 10 billion share repurchase program, but that doesn't mean it doesn't have room to make deals. FiercePharma News
Page 2 of 3123
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS